[Skip to Content]
[Skip to Content Landing]
Editorial
November 20, 2002

Hypertension Control and Kidney DiseaseSome Questions Answered, Many Remain

Author Affiliations

Author Affiliation: Department of Epidemiology and Social Medicine, Albert Einstein College of Medicine, Bronx, NY.

JAMA. 2002;288(19):2466-2467. doi:10.1001/jama.288.19.2466

The African American Study of Kidney Disease and Hypertension (AASK) compared renal outcomes at different blood pressure goals with alternate antihypertensive drugs in patients with hypertensive nephrosclerosis. The primary end point was change in the glomerular filtration rate (GFR) with a secondary clinical composite end point composed of end-stage renal disease (ESRD), a threshold decline in GFR, and all-cause mortality. The results of this trial, reported in this issue of THE JOURNAL, are unlikely to satisfy physicians caring for patients like those in AASK.1

First Page Preview View Large
First page PDF preview
First page PDF preview
×